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SUMMARY Subungual melanoma is an uncommon form of acral 
melanoma that arises within the nail bed. The incidence for acral 
melanomas is similar worldwide, but the proportion is higher in 
dark-skinned individuals. The subungual form represents about 
2% of cutaneous non-sun induced melanomas in the western 
world, and up to 75% in Africans, 10% in Japanese, and 25% in 
the Chinese of Hong Kong. Up to 33% of subungual melanomas 
are amelanotic. Black pigmentation of the adjacent nail fold, termed 
Hutchinson’s sign, may be a diagnostic clue. Non-specific features 
and symptoms along with a high incidence of amelanosis often lead 
to delayed diagnosis, disease progression, and a poor prognosis 
with challenging treatment options. 
KeY woRdS: Subungual tumor, melanoma, acral lentiginous 
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IntRodUCtIon
Subungual melanomas (SM) are uncommon 
malignancies of the nail which represent 0.7% to 
3.5% of cutaneous melanomas diagnosed in the 
general population (1-3). SM is a distinct variant 
of acral melanomas, often with histology charac-
teristic of acral lentiginous-type melanomas (4). 
The incidence of SM is similar for all ethnicities, 
although a higher proportion of acral lentiginous 
and subungual melanoma occurs in dark-skinned 
patients (5). Subungual melanoma survival rates 
remain poor when compared to melanoma of oth-
er parts of the body (6). Low survival rates are due 
to late detection. To facilitate early diagnosis, SM 
guidelines have been promulgated (1,7). Treat-
ment of subungual melanoma remains surgical, 
with wide local excision and amputation as pri-
mary modalities.
HIStoRY
The first clinical description of SM was made in 
1834 by Boyer (8) in a 58-year-old man’s fifth digit 
of the hand. In 1886, Hutchinson (9) described 
melanomas of the nail bed, which he referred to as 
melanotic whitlow due to its resemblance to her-
petic infection of the hand. His initial description 
stated: “...Careful observation will find, at the edge 
of the inflamed nail, a little border of coal black co-
lour, and this however slightly marked, must be al-
lowed to make the diagnosis. I have seen at least 
half a dozen of these cases. Early amputation is 
demanded…” (9). 
etIologY
SM, though rare, may occur in any patient 
worldwide. Overall, melanomas are a byproduct of 
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genetic and environmental factors, although sun 
exposure is unrelated in some forms (10). SMs 
have not been linked with sun exposure. In fact, 
the nail plate is a barrier to UVB radiation (5). SM 
may first be evident as a split nail, nail bed swelling, 
or crusty ulceration. Early literature has suggested 
that SM may be a direct result of trauma (11,12); 
however, the majority of analyses do not support 
such causation (2,13,14). One study showed a 
20% incidence of nail injury within the 20-year pe-
riod prior to SM diagnosis (6,15). In a cohort of 
Japanese patients, a history of trauma in the af-
fected digit was present in up to 44% (7). A 2002 
study maintains the possibility of injury as etiology 
factor, as trauma induced proliferation may mutate 
melanocytes (16). However, we believe that the 
relationship is incidental, with trauma serving to 
bring awareness to the affected digit (2). 
epIdeMIologY
SMs are most commonly seen in people aged 
50 to 70 years. Although the same incidence of 
melanoma exists among racial groups, dark com-
plexion persons have a higher proportion of this 
subtype of melanoma since they have a lower 
incidence of sun-induced melanoma (5). SM ac-
counts for 1% to 3% of all cutaneous melanomas 
in the white population, up to 75% of African mela-
nomas, about 10% of Japanese melanomas, and 
25% of melanomas in the Chinese of Hong Kong 
(4,17-20). Conversely, other forms of melanoma 
are more prevalent in lighter skinned populations 
and are related to sun exposure (4). The great toe 
or thumb are primarily affected in SM, account-
ing for 75% to 90% of cases (4). In one Japanese 
study, 19% of all diagnosed melanomas involved 
the nail (21). Several other studies in Japan have 
shown that melanoma in the acral regions, includ-
ing the nails of the digits, remain the most com-
mon type (7). Acral melanomas have a slight pre-
ponderance of female over male cases (4).  
ClInICAl MAnIfeStAtIonS 
SMs arise from the nail matrix, but may involve 
other components including the proximal nail fold, 
nail bed, and hyponychium. They often begin as 
brown-black discolorations of the nail bed which 
may appear in the form of bands or streaks (Fig. 
1). This discoloration will progress to thickening, 
splitting, or full destruction of the nail with pain, 
inflammation, discharge and pigmentary change 
possible in the surrounding areas (14). In a study 
by Takematsu et al. (7), 31% of SMs began as 
below nail pigmented streaks and became ulcer-
ated or painful after several years. With disease 
advancing over many years, involvement of the 
eponychium and paronychium is common. The 
widening, dark, and longitudinal nail streak may 
initially be termed melanonychia striata, which 
when broad, darkly pigmented, or with blurred lat-
eral borders merits special consideration of SM 
(22). Black pigmentation of the adjacent nail fold 
is an ominous feature, termed Hutchinson’s sign. 
Unfortunately, 1/5 to 1/3 of SMs appear amelanot-
ic, further challenging recognition (6,14,23).
SM, similar to other types of melanoma, has a 
biphasic growth pattern with horizontal and verti-
cal components. Additionally, the tumor thickness 
is the most important prognostic factor for this dis-
ease (6). In one study, Clark levels for invasive-
ness were at Level IV or V in 33 of 49 patients 
at the time of diagnosis (17). This same study 
showed thicker SM of the toe than finger (mean 
3.5 vs. 2.5 mm; P=0.005). Lymph node involve-
ment may be clinically apparent in some SMs. An 
early study showed that 7 of 20 patients had ipsi-
lateral upper extremity nodal involvement and 7 
of 14 had ipsilateral groin involvement for primary 
SMs in those respective regions (2).
dIffeRentIAl dIAgnoSIS
Differential diagnosis is wide for SM. Subun-
gual pigmentation may be caused by fungal in-
fection, subungual hematoma, foreign material, 
drugs, or systemic conditions. Other causes may 
be neoplastic, as in pigmented Bowen disease or 
benign melanocytic nevi (4,24). Table 1 outlines 
conditions that may resemble SM.
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A principal task is to determine whether nail 
changes are of melanocytic or nonmelanocytic 
origin. This may be done with clinical and dermo-
scopic examination. Subungual hematoma and 
fungal infections tend to have homogeneous pig-
mentary distribution, whereas melanocytic condi-
tions appear granular with cellular inclusions of 
melanin (24). Furthermore, subungual hematoma 
will appear with a reddish to reddish-black color de-
pending on the time of the bleed. Bloodspots with 
a proximally round shape tapering to a filamentous 
end may be evident (24). It is wrong to exclude a 
diagnosis of melanoma if hemorrhage is present 
because secondary bleeds may still occur in SM 
(24). Fungal infections clinically suggesting SM in-
clude those caused by Scytalidium dimidiatum and 
Trichophyton rubrum, entities known to produce 
black pigmentation (25,26) (Fig. 2). Nail discolor-
ation by epithelial hyperpigmentation may mimic 
SM when appearing as gray bands composed of 
homogeneous gray lines. Brown-black colored 
bands on the nail plate and regular linear patterns 
suggest melanocytic hyperplasia, whereas irregu-
lar patterns hint at melanoma (24) (Fig. 3).
Drug, hormonal, and nutritional causes of lon-
gitudinal melanonychia have been noted. In one 
small group of HIV patients, 67% on azidothymi-
dine (AZT) treatment demonstrated such discol-
oration (27). Addison’s disease, Cushing’s syn-
drome, and hypothyroidism produce pigmentary 
nail changes (28,29). A bluish-black discoloration 
has been reported in vitamin B12 and folate defi-
cient patients and is reversible with dietary supple-
mentation (30).
The distinction between nevi of the nail ma-
trix and SM must be made. A benign nevus may 
be identified in children and may be congenital. 
It is colored light brown to black and can have a 
pseudo-Hutchinson sign, in which banding pig-
mentation is visible through a translucent cuticle. 
Junctional nevi are more common than compound 
nevi in this condition, and the heavily pigmented 
nature of some nevi may simulate melanoma (24). 
In comparison, SM will often have a broader dark 
brown band with blurred lateral borders. Rapid 
growth leads to bands which are not parallel and 
hints at an ominous diagnosis (24).  
Table 1 and Table 2 list more conditions to con-
sider in the diagnostic work up of a patient with 
black nail disease.
figure 1. Subungual melanoma. (from ref. 4, with 
permission of Blackwell)
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figure 2. Black nail in a patient with onychomy-
cosis. figure 3. Longitudinal melanonychia.
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SMs have a unique histopathologic profile due 
to the involvement of the nail unit. Major features 
include an increased number of melanocytes in 
the basal layer of the specimen. This layer is en-
tirely full of pleomorphic melanocytes with bizarre 
nuclei. Many pagetoid cells, characterized by ir-
regularly shaped nests of plump melanocytes, are 
present (7). Melanoma in situ has these aforemen-
tioned features but is devoid of stromal invasion. 
In many cases, melanin pigment will be found in 
the epidermis of the lower third of the nail matrix 
(31). Invasive nail melanoma will show higher me-
lanocyte counts (2-3 times that of benign melano-
nychia), multinucleation, atypia, and florid paget-
oid spread of melanocytes (31). Inflammation is 
also present in advanced melanoma unlike benign 
melanonychia.
Histology of SM may be consistent with super-
ficial spreading (50%), acral lentiginous (67%), or 
sometimes both forms of melanoma.(31). Spe-
cifically, acral lentiginous melanoma (ALM) is a 
subtype involving the volar areas. It is character-
ized by acanthosis, elongation of rete ridges, and 
lentiginous proliferation of atypical melanocytes 
in the epidermis (7). Basal keratinocytes become 
replaced by cytologically malignant melanocytes 
in ALM. Histology demonstrates greater than 6.5 
melanocytes/mm of basal layer length. Further-
more, lymphoid cells infiltrate the underlying der-
mis in ALM. 
The Fontana-Masson stain, which identifies 
melanin, may be helpful in the diagnosis of mela-
noma, including SM. The immunostain Melan-A 
(monoclonal antibody A103 or MART-1), S-100, 
HMB-45, and NKI/C3 protein markers have similar 
utility. The S-100 marker is the most sensitive one 
(32). Unfortunately, such stains are not definitive, 
as 20%-33% of nail unit melanomas are amela-
notic (1).
dIAgnoStIC AppRoACH
Frequently, 2-3 years pass before a patient 
seeks medical evaluation for a nail finding sug-
gesting SM (7). Diagnosis is established by bi-
opsy, though certain clinical features are indica-
tive. A biopsy specimen should include part of the 
nail-bed, nail-plate, and nail matrix (6,33). A repeat 
biopsy may be warranted if the initial specimen is 
inconclusive. Nail specific ABCDEF guidelines are 
helpful in assessment and are outlined in Table 3 
(1). Hutchinson’s sign, or black discoloration of the 
proximal nail fold, is suggestive of SM with poor 
prognosis. This feature has inherent flaws, as it 
has no use in amelanotic melanoma. Furthermore, 
a Hutchinson’s-like sign may be associated with 
Laugier-Hunziker syndrome, ethnic pigmentation, 
infection, or use of specific medications. 
Clinical evaluation may include dermoscopy 
(34). It is helpful to closely evaluate any pigment-
ed banding patterns and the free edge of the nail 
(24).The use of a gel, such as ultrasound gel as 
a type of immersion medium, decreases viscos-
ity and fills any cavities while permitting the der-
matoscope to stay on the nail plate without rolling 
off. Grayish homogeneous bands or thin gray lines 
evident with dermoscopy are suggestive of benign 
melanocytic hyperplasia or ethnic pigmentation. 
This phenomenon of epithelial hyperpigmentation 
without accompanying melanocytic hyperplasia 
is seen in a lentigo, drug-induced pigmentation, 
and ethnic pigmentation (24). Brown to black pig-
mentation in an irregular longitudinal pattern with 
nail plate erosion, Hutchinson’s sign, and blood 
spots (seen in 5% of pigmented melanomas), are 
suggestive SM signs (35). The brown pigmented 
band, composed of multiple thin brown lines, can 
be regular or irregular and is caused by melano-
cytic hyperplasia in a nevus or melanoma (24). 
Dermoscopy of amelanotic melanoma of the nail 
may demonstrate remnants of pigment, linear ir-
regular vessels, and erosion of the nail plate (35). 
Additional assessment includes examination of 
axillary and inguinal lymph nodes, which may in-
clude use of computed tomography (36). American 
Joint Commission on Cancer (AJCC) staging, lev-
el of invasion, ulceration, and Breslow and Clark’s 
levels should be determined as well (36). Specifi-
cally, classification of melanomas by Clark’s lev-
els can be challenging in the nail because of the 
unique anatomy. Modifications have been made 
table 3. Nail specific ABCDEF guidelines to assist 
in risk assessment of subungual melanoma
A Age – peaks at 50 to 70 years old
African, Japanese, Chinese, and Native 
American are dominant
B Brown-black band often >3mm with irregular 
border
C Change in size and growth rate, or failed 
improvement with adequate treatment of 
alternative cause
D Digit – 1) thumb 2) big toe 3) index finger; 
usually only one affected digit
E Extension of discoloration, Hutchinson’s sign
F Family history of melanoma
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to overcome this obstacle. For example, Clark’s 
Level V is defined as SM invasion to the underly-
ing bone, as subcutaneous fat is usually absent 
(37).    
pRognoSIS
Prognosis is poor for SM, often due to the late 
stage at diagnosis. Five-year survival rates for the 
invasive type average around 40% (2,7). How-
ever, rates may be as low as 18% for five-year 
survival as shown by Feibleman et al.(38). A study 
of 49 patients showed less favorable outcomes 
for invasive SM of the toe when compared to the 
finger (40% vs. 72% 5-year survival) (17). Black 
Americans have a 3.5% lower survival rate than 
White Americans with SM (confidence interval 1.4-
8.6) (36). The most significant factor influencing 
prognosis is the presence of lymph node involve-
ment, emphasizing the value of a complete exam 
for these patients (17). Prognosis may also be 
impacted by gender, as studies have shown the 
majority of long-term survivors seem to be women 
(67% vs. 50% overall long term survival (39)). Mi-
totic rates of melanocytes may also be predictive 
of prognosis, in an inverse relationship to survival 
(38). Clinical thickness of the tumor also relates to 
prognosis. One study showed ≥4mm thick tumors 
resulted in an outcome of only 25% disease free 
survival at 2 years (17).
MAnAgeMent
Treatment options for SM, specifically early 
amputation, remain similar to those proposed ini-
tially by Hutchinson in the 1800s (9). Other modal-
ities, such as laser surgery, have no definitive role 
in treatment. Appropriate surgical management 
involves wide local excision of the in situ form and 
often amputation when SM is invasive (17). Ra-
dial margins should be determined by the Bres-
low depth. A 1-2 cm margin is preferred in patients 
with a 2-mm deep invasive melanoma, however, 
due to the paucity of soft tissue in the nail, ampu-
tation must often be performed to accommodate 
the suggested margins (17). Additionally, nodal 
dissection is recommended in patients with clini-
cally positive lymph nodes. 
Conservative levels of amputation are safe and 
will not affect recurrence if negative margins are 
achieved (40). One 2003 study suggested that lim-
ited excision with three-dimensional histology had 
similar survival outcomes when compared to tradi-
tionally amputated patients (41). Another analysis 
also advocated a conservative digit sparing ap-
proach and showed no recurrence in 75% of pa-
tients at 6-year follow up (42). Mohs micrographic 
surgery to refine excision has been employed with 
some success (43). Brodland (44) showed 86% 
survival at 7.7 years in a small retrospective US 
study of Mohs micrographic surgery for nail mela-
noma. Such research represents the continued ef-
fort for newer treatment modalities to conserve a 
functionally precious part of the human anatomy 
(45,46). Aggressive amputation and digit sparing 
approaches such as Mohs microsurgery remain 
options mandating careful scrutiny individualized 
for each patient (44).  
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